Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD

  • Marques, Vanda
  • Afonso, Marta Bento
  • Bierig, Nina
  • Duarte-Ramos, Filipa
  • Santos Laso, Álvaro
  • Jiménez Agüero, Raúl
  • Eizaguirre Letamendia, Emma
  • Bujanda Fernández de Pierola, Luis
  • Pareja Megía, María J.
  • Luís, Rita
  • Costa, Adília
  • Machado, Mariana Verdelho
  • Alonso, Cristina
  • Arretxe Oliden, Enara
  • Alustiza Echeberria, José María
  • Krawczyk, Marcin
  • Lammert, Frank
  • Tiniakos, Dina G.
  • Flehmig, Bertram
  • Cortez-Pinto, Helena
  • Bañales Asurmendi, Jesús María
  • Castro, Rui E.
  • Normann, Andrea
  • Rodrigues, Cecilia M. P.
[EN] Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease where liver biopsy remains the gold standard for diagnosis. Here we aimed to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor 1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with the metabolome. Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD, 31 controls) and correlated with clinical data, histology, genetic parameters, and serum metabolomics. Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC 0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between obese and non-obese healthy controls, suggesting that obesity is not a confounding factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis (NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC 0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p<0.05), but combination with international normalized ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01). Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis., CR was funded by FEDER through the COMPETE program and by national funds through Fundação para a Ciência e a Tecnologia (PTDC/MED-FAR/29097/2017—LISBOA-01- 0145-FEDER-029097) and by European Horizon 2020 (H2020- MSCA-RISE-2016-734719). This work was also supported by Fundação para a Ciência e Tecnologia (PD/BD/135467/2017) and Portuguese Association for the Study of Liver/MSD 2017. JB was funded by Spanish Carlos III Health Institute (ISCIII) (PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129 and CPII19/00008), co-financed by Fondo Europeo de Desarrollo Regional (FEDER), Instituto de Salud Carlos III (CIBERehd, Spain), La Caixa Scientific Foundation (HR17-00601), Fundación Científica de la Asociación Española Contra el Cáncer, and European Horizon 2020 (ESCALON project: H2020-SC1-BHC-2018-2020).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

  • Caballero Camino, Francisco Javier
  • Rivilla de la Cruz, Iván
  • Herráez Aguilar, Elisa
  • Briz Sánchez, Oscar
  • Santos Laso, Álvaro
  • Izquierdo Sánchez, Laura
  • Lee-Law, Pui Y.
  • Rodrigues, Pedro M.
  • Muñoz Garrido, Patricia
  • Jin, Sujeong
  • Peixoto, Estanislao
  • Richard, Seth
  • Gradilone, Sergio A.
  • Perugorria Montiel, María Jesús
  • Esteller, Manel
  • Bujanda Fernández de Pierola, Luis
  • Marín, José J. G.
  • Bañales Asurmendi, Jesús María
  • Cossío Mora, Fernando Pedro
Background and Aims Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. Approach and Results Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. Conclusions These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs., Supported by the Spanish Carlos III Health Institute (ISCIII; J.M. Banales: FIS PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129; M.J. Perugorria: PI14/00399, PI17/00022; J.J.G. Marin: FIS PI16/00598) cofinanced by "Fondo Europeo de Desarrollo Regional" (FEDER); CIBERehd (ISCIII): J.M. Banales, M.J. Perugorria, L. Bujanda, and J.J.G. Marin; Spanish Ministry of Economy and Competitiveness (M. J. Perugorria: Ramon y Cajal Program RYC-2015-17755); IKERBASQUE, Basque foundation for Science (M.J. Perugorria and J.M. Banales), Spain; "Junta de Castilla y Leon" (J.J.G. Marin: SA06P17); " Diputacion Foral Gipuzkoa" (J.M. Banales: DFG15/010, DFG16/004; M.J. Perugorria: DFG18/114, DFG19/081), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M. Banales), Department of Health of the Basque Country (J.M. Banales: 2017111010; M.J. Perugorria: 2019111024), and Euskadi RIS3 (J.M. Banales: 2016222001, 2017222014, and 2018222029; 2019222054); La Caixa Scientific Foundation (J.M. Banales: HR17-00601); "Fundacion Cientifica de la Asociacion Espanola Contra el Cancer" (AECC Scientific Foundation, to J.M. Banales and J.J.G. Marin); and "Centro Internacional sobre el Envejecimiento", Spain (J.J.G. Marin: OLD-HEPAMARKER, 0348-CIE-6-E). F.J. Caballero-Camino was funded by the Spanish Ministry of Science and Innovation (BES-2014-069148), A. Santos-Laso by the Basque Government (PRE_2018_2_0195), and Pui Y. Lee-Law by the European Association for the Study of the Liver (EASL; Sheila Sherlock Award). The Spanish Ministry of Science and Innovation supported F. P. Cossio: (CTQ2016-80375-P and CTQ2014-51912-REDC) as well as the Basque Government (F.P. Cossio: IT-324-07). I. Rivilla had a postdoctoral contract from the Donostia International Physics Center.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma

  • Lewinska, Monika
  • Santos Laso, Álvaro
  • Arretxe Oliden, Enara
  • Alonso, Cristina
  • Zhuravleva, Ekaterina
  • Jiménez Agüero, Raúl
  • Eizaguirre Letamendia, Emma
  • Pareja Megía, María J.
  • Romero Gómez, Manuel
  • Arrese, Marco
  • Suppli, Malte P.
  • Knop, Filip K.
  • Oversoe, Stine Karlsen
  • Villadsen, Gerda Elisabeth
  • Decaens, Thomas
  • Carrihlo, Flair Jose
  • Oliveira, Claudia P.M.S.
  • Sangro, Bruno
  • Rodríguez Macías, Rocío Isabel
  • Bañales Asurmendi, Jesús María
  • Andersen, Jesper B.
[EN]Background: Non-alcoholic fatty liver disease (NAFLD) is affecting more people globally. Indeed, NAFLD is a spectrum of metabolic dysfunctions that can progress to hepatocellular carcinoma (NAFLD-HCC). This development can occur in a non-cirrhotic liver and thus, often lack clinical surveillance. The aim of this study was to develop non-invasive surveillance method for NAFLD-HCC. Methods: Using comprehensive ultra-high-performance liquid chromatography mass-spectrometry, we investigated 1,295 metabolites in serum from 249 patients. Area under the receiver operating characteristic curve was calculated for all detected metabolites and used to establish their diagnostic potential. Logistic regression analysis was used to establish the diagnostic score. Findings: We show that NAFLD-HCC is characterised by a complete rearrangement of the serum lipidome, which distinguishes NAFLD-HCC from non-cancerous individuals and other HCC patients. We used machine learning to build a diagnostic model for NAFLD-HCC. We quantified predictive metabolites and developed the NAFLD-HCC Diagnostic Score (NHDS), presenting superior diagnostic potential compared to alpha-fetoprotein (AFP). Patients' metabolic landscapes show a progressive depletion in unsaturated fatty acids and acylcarnitines during transformation. Upregulation of fatty acid transporters in NAFLD-HCC tumours contribute to fatty acid depletion in the serum. Interpretation: NAFLD-HCC patients can be efficiently distinguished by serum metabolic alterations from the healthy population and from HCC patients related to other aetiologies (alcohol and viral hepatitis). Our model can be used for non-invasive surveillance of individuals with metabolic syndrome(s), allowing for early detection of NAFLD-HCC. Therefore, serum metabolomics may provide valuable insight to monitor patients at risk, including morbidly obese, diabetics, and NAFLD patients., We thank the participating patients and their families as well as clinical staffat all contributing centres. We thank the French Liver Biobanks network -INCa (BB-0033-00085) for the contribution of NAFLD-HCC samples (participating hospitals: Beaujon, Bordeaux, Grenoble, Henri-Mondor, Paris-SUD, and Rennes). We thank the section of Biostatistics at Department of Public Health, University of Copenhagen for statistical advice. The results are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.We thank all funding sources: The laboratory of JBA is supported by the Novo Nordisk Foundation (14040, 0058419), Danish Cancer Society (R98-A6446, R167A10784, R278-A16638), and the Danish Medical Research Council (4183-00118A, 1030-00070B). Data used for validation in this study provided by JMB was funded by the Spanish Ministry of Economy and Competitiveness and 'Instituto de Salud Carlos III' grants (PI18/01075, Miguel Servet Programme CON14/00129 and CPII19/00008) co-financed by 'Fondo Europeo de Desarrollo Regional' (FEDER); CIBERehd, Spain; IKERBASQUE, Basque foundation for Science, Spain; BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD); Department of Health of the Basque Country (2017111010), Euskadi RIS3 (2019222054, 2020333010); Department of Industry of the Basque Country (Elkartek: KK-2020/000 08), AECC Scientific Foundation and European Commission Horizon 2020 program (ESCALON project no.: 825510). Similarly, MAJ was funded by grants from the Fondo Nacional De Ciencia y Tecnologia de Chile (FONDECYT #1191145 to M.A.) and the Comision Nacional de Investigacion, Ciencia y Tecnologia (CONICYT, AFB170005, CARE Chile UC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

  • Lachiondo-Ortega, Sofía
  • Rejano-Gordillo, Claudia María
  • Simón, Jorge
  • Lopitz-Otsoa, Fernando
  • Delgado, Teresa C.
  • Mazan-Mamczarz, Krystyna
  • Goikoetxea-Usandizaga, Naroa
  • Zapata-Pavas, L. Estefanía
  • García-del Río, Ana
  • Guerra, Pietro
  • Peña-Sanfélix, Patricia
  • Hermán-Sánchez, Natalia
  • Al-Abdulla, Ruba
  • Fernández-Rodríguez, Carmen
  • Azkargorta, Mikel
  • Velázquez-Cruz, Alejandro
  • Guyon, Joris
  • Martín, César
  • Zalamea, Juan Diego
  • Egia-Mendikute, Leire
  • Sanz-Parra, Arantza
  • Serrano-Maciá, Marina
  • González-Recio, Irene
  • Gonzalez-López, Monika
  • Martínez-Cruz, Luis Alfonso
  • Pontisso, Patrizia
  • Aransay, Ana M.
  • Barrio, Rosa
  • Sutherland, James D.
  • Abrescia, Nicola G. A.
  • Elortza, Félix
  • Lujambio, Amaia
  • Banales, Jesús M.
  • Luque, Raúl M.
  • Gahete, Manuel D.
  • Palazón, Asís
  • Ávila, Matías A.
  • Marín, José J. G.
  • De, Supriyo
  • Daubon, Thomas
  • Diaz-Quintana, Antonio
  • Díaz-Moreno, Irene
  • Gorospe, Myriam
  • Rodríguez, Manuel S.
  • Martínez-Chantar, María Luz
© 2024 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., The posttranslational modification of proteins critically influences many biological processes and is a key mechanism that regulates the function of the RNA-binding protein Hu antigen R (HuR), a hub in liver cancer. Here, we show that HuR is SUMOylated in the tumor sections of patients with hepatocellular carcinoma in contrast to the surrounding tissue, as well as in human cell line and mouse models of the disease. SUMOylation of HuR promotes major cancer hallmarks, namely proliferation and invasion, whereas the absence of HuR SUMOylation results in a senescent phenotype with dysfunctional mitochondria and endoplasmic reticulum. Mechanistically, SUMOylation induces a structural rearrangement of the RNA recognition motifs that modulates HuR binding affinity to its target RNAs, further modifying the transcriptomic profile toward hepatic tumor progression. Overall, SUMOylation constitutes a mechanism of HuR regulation that could be potentially exploited as a therapeutic strategy for liver cancer., This work was supported by grants to M.L.M.-C. from Departamento de Industria del Gobierno Vasco, Spain; Ministerio de Ciencia e Innovación, Spain (grant no. PID2020-117116RB-I00); European Regional Development Fund (ERDF), EU; and CIBERehd, which is funded by Instituto de Salud Carlos III (ISCIII), Spain. M.L.M.-C. and J.S. received funding from Ministerio de Ciencia e Innovación (grant no. RTC2019-007125-1) and ISCIII (grant no. DTS20/00138). M.L.M.-C. and R.M.L. acknowledge Ministerio de Ciencia e Innovación (grant no. RED2022-134397-T). M.L.M.-C. and J.M.B. were awarded with a grant from Fundación la Caixa, Spain (grant no. HR17-00601). M.L.M.-C., J.M.B., M.A.A., and J.J.G.M. acknowledge financial support from Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Spain. M.S.R. recognizes funding from Fondo Sectorial de Investigación SRE - CONACYT, Mexico (grant no. 0280365); Horizon 2020 Research and Innovation Program funded under Marie Skłodowska-Curie Actions, EU (grant no. 765445); and REPÈRE and Programme de Prématuration from Région Occitanie, France. M.G., S.D., and K.M.-M. were supported by the National Institute on Aging (NIA), National Institutes of Health (NIH), US (grant no. Z01-AG000511-23). I.D.-M. is grateful for the grants received from Junta de Andalucía, Spain (grant no. BIO-198, US-1254317, P18-FR-3487, and P18-HO-4091); Ministerio de Ciencia, Innovación y Universidades, Spain (grant no. PGC2018-096049-BI00); and Fundación Ramón Areces, Spain. T.D. acknowledges Fondation ARC, France (grant no. 208084). J.J.G.M. was supported by Junta de Castilla y León, Spain (grant no. SA063P17); Fundación La Marató TV3, Spain (grant no. 201916-31); ISCIII (grant no. PI19/00819); CIBERehd; and ERDF (grant no. OLD-HEPAMARKER). M.A.A. recognizes Gobierno de Navarra, Spain (grant no. GºNa 42/21); Eurorregión Nueva Aquitania-Euskadi-Navarra, Spain; Ministerio de Ciencia e Innovación (grant no. PID2019-104878RB-I00); and CIBERehd. A.P. expresses gratitude to the European Research Council (ERC), EU (grant no. 804236) for their support. M.D.G. received financial support from Junta de Andalucía (grant no. PEMP-0036-2020 and BIO-0139); Ministerio de Universidades, Spain (grant no. FPU20/03957); ISCIII (grant no. PI20/01301), Fundación Sociedad Española de Endocrinología y Nutrición (FSEEN), Spain; CIBERehd; and CIBERobn, which is also funded by ISCIII. J.M.B. acknowledges Euskadi RIS3 (grant no. 2019222054, 2020333010, and 2021333003) and Elkartek programs from Gobierno Vasco (grant no. KK-2020/00008); ISCIII (grant no. PI18/01075, CPII19/00008, and PI21/00922); CIBERehd; PSC Support, UK; AMMF The Cholangiocarcinoma Charity, UK (grant no. EU/2019/AMMFt/001); Horizon 2020 Research and Innovation Program (grant no. 825510); ERDF; and PSC Partners Seeking a Cure, US. A.L. received financial support from the Damon Runyon-Rachleff Innovation Award, US (grant no. DR52-18) and the MERIT Award (R37) from the National Cancer Institute (NCI), NIH (grant no. R37CA230636). F.E. expresses his gratitude to ProteoRed from ISCIII (grant no. PT13/0001/0027) and CIBERehd. N.G.A.A. was funded by Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-095700-B-I00). R.B. acknowledges financial support from Gobierno Vasco (grant no. IT1165-19); Ministerio de Economía, Industria y Competitividad, Spain (grant no. SAF2017-90900-REDT); Ministerio de Economía, Industria y Competitividad, ERDF (grant no. BFU2017-84653-P); Ministerio de Ciencia e Innovación (grant no. PID2020-114178GB-I00); and Horizon 2020 funded under Marie Skłodowska-Curie Actions (grant no. 765445-EU). A.M.A. acknowledges CIBERehd. L.A.M.-C. obtained grants from Ministerio de Economía y Competitividad (grant no. CSD2008-00005); Ministerio de Economía, Industria y Competitividad (grant no. BFU2016-77408-R); ISCIII; and EJP RD, EU (grant no. EJPRD19-040). I.G.-R. was supported by Ministerio de Economía, Industria y Competitividad (grant no. BES-2017-080435 ). M.S.-M. is grateful to the AECC, Sede de Bizkaia, Spain for the financial support. J.D.Z. was awarded with a grant from Ministerio de Economía, Industria y Competitividad (grant no. SEV-2016-0644-18-2). C.M. acknowledges Gobierno Vasco (grant no. IT-1264-19) and Ministerio de Ciencia e Innovación (grant no. PID2022-136788OB-I00). A.V.-C. was supported by Ministerio de Educación, Cultura y Deporte, Spain (grant no. FPU016/01513). C.F.-R. thanks Tekniker, Spain and CIC bioGUNE, Spain for financial support. A.G.-d.R. was funded by Bikaintek program from Gobierno Vasco (grant no. 48-AF-W1-2019-00012). N.G.-U. obtained a grant from Gobierno Vasco. T.C.D. expresses gratitude to AECC. J.S. received financial support from CIBERehd. C.M.R.-G. was supported by Ayudas a la Recualificación Margarita Salas from Universidad de Extremadura, Ministerio de Universidades financed by NextGenerationEU., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

  • Caballero-Camino, F. J.
  • Rivilla, I.|||0000-0003-1984-7183
  • Herraez, Elisa
  • Briz, O.
  • Santos-Laso, A.|||0000-0001-9810-4913
  • Izquierdo-Sanchez, Laura
  • Lee-Law, P. Y.
  • Rodrigues, P. M.|||0000-0001-6193-7436
  • Munoz-Garrido, P.
  • Jin, S.
  • Peixoto, E.
  • Richard, S.
  • Gradilone, S. A.
  • Perugorria, M. J.
  • Esteller, M.|||0000-0003-4490-6093
  • Bujanda, Luis|||0000-0002-4353-9968
  • Marin, J. J. G.
  • Banales, Jesus|||0000-0002-5224-2373
  • Cossío, Fernando P.|||0000-0002-4526-2122
Background and Aims: Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. Approach and Results: Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. Conclusions: These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)

  • Riaño, Ioana|||0000-0001-8410-2706
  • Martín, Leticia
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Serrano, Trinidad
  • Núñez, Oscar
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Rodrigues, Pedro M.
  • Perugorria, Maria J.
  • Banales, Jesus|||0000-0002-5224-2373
  • Arenas, Joaquín|||0000-0002-2877-5049
Pravastatin has demonstrated anti-tumor activity in preclinical and clinical studies. This multicentric randomized double-blind placebo-controlled phase II study (NCT01418729) investigated the efficacy and safety of sorafenib + pravastatin combination on the overall survival (OS) and time to progression (TTP) of patients with advanced hepatocellular carcinoma (aHCC). A total of 31 patients were randomized. Median OS did not differ between both groups (12.4 months for the sorafenib + pravastatin group vs. 11.6 months for the control group). Of note, however, the radiological TTP was higher in patients treated with sorafenib + pravastatin than in the control group (9.9 months vs. 3.2 months; p = 0.008). Considering all the study population, the presence of portal vein thrombosis (PVT) was associated with worse OS, being lower in patients with PVT compared to patients without PVT (6.3 months vs. 14.8 months; p = 0.026). Data also showed a decrease in OS in patients with vascular invasion (VI) compared to patients who did not present it (6.3 months vs. 14.8 months; p = 0.041). The group of patients without dermatological events (DE) showed lower OS (6.9 months vs. 14.5 months; p = 0.049). In conclusion, combination of sorafenib + pravastatin was safe and well-tolerated, prolonging the TTP of patients with aHCC but not improving the OS compared to sorafenib + placebo. The absence of PVT and VI and the development of DE are positive prognostic factors of sorafenib response
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lifetime Dual Disorder Screening and Treatment Retention, A Pilot Cohort Study

  • Puértolas-Gracia, Beatriz
  • Barbaglia, María Gabriela|||0000-0002-6501-7079
  • Gotsens, Mercè|||0000-0003-2952-2024
  • Pares Badell, Oleguer|||0000-0003-2568-7550
  • Brugal, María Teresa|||0000-0003-0580-676X
  • Torrens, Marta
  • Treviño, Lara
  • Rodríguez-Díaz, Cconcepción
  • Vázquez-Vázquez, José María
  • Pascual, Alicia
  • Coromina-Gimferrer, Marcela
  • Jiménez-Dueñas, Míriam
  • Oliva, Israel
  • González, Erick
  • Mestre, Nicanor
  • Bartroli, Montserrat|||0000-0002-4553-9961
The coexistence of a substance use disorder and another mental disorder in the same individual has been called dual disorder or dual diagnosis. This study aimed to examine the prevalence of lifetime dual disorder in individuals with alcohol or cocaine use disorder and their retention in treatment. We conducted a pilot cohort study of individuals (n = 1356) with alcohol or cocaine use disorder admitted to treatment in the public outpatient services of Barcelona (Spain) from January 2015 to August 2017 (followed-up until February 2018). Descriptive statistics, Kaplan-Meier survival curves and a multivariable Cox regression model were estimated. The lifetime prevalence of screening positive for dual disorder was 74%. At 1 year of follow-up,.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

  • Ampuero, Javier|||0000-0002-8332-2122
  • Aller, Rocio
  • Gallego-Durán, Rocío
  • Crespo García, Javier|||0000-0001-8248-0172
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • García-Monzón, Carmelo
  • Gómez-Camarero, Judith
  • Caballería, Joan
  • Lo Iacono, Oreste
  • Ibáñez Samaniego, Luis|||0000-0002-0309-2727
  • García-Samaniego, Javier|||0000-0002-9974-0855
  • Albillos, Agustín|||0000-0001-9131-2592
  • Francés, Rubén
  • Fernández-Rodríguez, Conrado
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Diago, Moises|||0000-0002-8583-2433
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Andrade, Raúl J.
  • Latorre, Raquel
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Escudero-García, Desamparados
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Pareja-Megia, María Jesús
  • Banales, Jesus|||0000-0002-5224-2373
  • Aspichueta, Patricia
  • Benlloch, Salvador|||0000-0002-0794-6937
  • Rosales, José Miguel
  • Turnes, Juan|||0000-0001-8426-6145
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
Background: MASLD can manifest as hepatocellular damage, which can result in mild elevation of aminotransferases. However, in some patients, MASLD presents with cholestatic pattern. Objective: To assess the impact of the biochemical pattern on the natural course of MASLD, including liver damage in histology, the accuracy of non-invasive tests(NITs), and prognosis. Methods: Multicenter study enrolling 2156 patients with biopsy-proven MASLD, who were classified based on their[ALT/ULN)]/[(ALP/ULN)] levels at the time of biopsy: (a) hepatocellular pattern(H),.
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

  • Martínez Arranz, Ibón
  • Bruzzone, Chiara
  • Noureddin, Mazen
  • Gil Redondo, Rubén
  • Mincholé, Itziar
  • Bizkarguenaga, Maider
  • Arretxe, Enara
  • Iruarrizaga Lejarreta, Marta
  • Fernández Ramos, David
  • Lopitz Otsoa, Fernando
  • Mayo, Rebeca
  • Embade, Nieves
  • Newberry, Elizabeth
  • Mittendorf, Bettina
  • Izquierdo Sánchez, Laura
  • Smid, Vaclav
  • Arnold, Jorge
  • Iruzubieta, Paula
  • Pérez Castaño, Ylenia
  • Krawczyk, Marcin
  • Marigorta, Urko M.
  • Morrison, Martine C.
  • Kleemann, Robert
  • Martín Duce, Antonio|||0000-0001-8751-9224
  • Hayardeny, Liat
  • Vitek, Libor
  • Bruha, Radan
  • Aller de la Fuente, Rocío
  • Crespo, Javier
  • Romero Gómez, Manuel
  • Banales, Jesús M.
  • Arrese, Marco
  • Cusi, Kenneth
  • Bugianesi, Elisabetta
  • Klein, Samuel
  • Lu, Shelly C.
  • Anstee, Quentin M.
  • Millet, Oscar
  • Davidson, Nicholas O.
  • Alonso, Cristina
  • Mato, José M.
14 p., Background and aims: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach and results: We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6 , and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A. Conclusions: Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification., National Institutes of Health (USA), Netherlands Organization for Applied Scientific Research (TNO) (Países Bajos), Newcastle NIHR Biomedical Research Center, Czech Ministry of Health, Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER), Departamento de Industria, Transición Energética y Sostenibilidad (Gobierno Vasco), Fundación La Caixa, Unión Europea, Fondo Nacional de Desarrollo Científico y Tecnológico (Fondecyt) (Chile), Comisión Nacional de Investigación, Ciencia y Tecnología (Chile), Agencia Nacional de Investigación y Desarrollo (ANID) (Chile)